strong buy CLDX: Celldex Therapeutics, Inc. Analyst Rating Updat
stop: $11
take profit: $17
--
Celldex Therapeutics, Inc. Analyst Rating Update
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks. The company received an average rating of 1 from 8 analysts. 8 have rated it as a strong buy.
Many analysts have commented on the company rating. Brokerage firm Jefferies maintains its rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX). As per the latest information, the brokerage house raises the price target to $36 per share from a prior target of $24. The shares have been rated Buy. The rating by the firm was issued on March 18, 2015.
Celldex Therapeutics, Inc. (NASDAQ:CLDX): The stock price is expected to reach $ 35.43 in the short term. The number of analysts agreeing with this consensus is 7. The higher estimate for the short term price target is at $45 while the lower estimate is at $24. The standard deviation of the price stands at $7.28.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) witnessed a decline in the market cap on Monday as its shares dropped 1.16% or 0.19 points. After the session commenced at $16.46, the stock reached the higher end at $16.5648 while it hit a low of $15.82. With the volume soaring to 1,791,904 shares, the last trade was called at $16.15. The company has a 52-week high of $32.82. The company has a market cap of $1,592 million and there are 98,595,000 shares in outstanding. The 52-week low of the share price is $12.11.
Celldex Therapeutics, Inc. has lost 24.36% in the last five trading days and dropped 39.76% in the last 4 weeks. Celldex Therapeutics, Inc. has dropped 38.5% during the last 3-month period . Year-to-Date the stock performance stands at -11.51%.
On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Celldex Therapeutics, Inc., Ellberger Larry had purchased shares worth of $82,950 in a transaction dated on August 13, 2015. A total of 5,000 shares were purchased at a price of $16.59 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Companys drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system.
take profit: $17
--
Celldex Therapeutics, Inc. Analyst Rating Update
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks. The company received an average rating of 1 from 8 analysts. 8 have rated it as a strong buy.
Many analysts have commented on the company rating. Brokerage firm Jefferies maintains its rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX). As per the latest information, the brokerage house raises the price target to $36 per share from a prior target of $24. The shares have been rated Buy. The rating by the firm was issued on March 18, 2015.
Celldex Therapeutics, Inc. (NASDAQ:CLDX): The stock price is expected to reach $ 35.43 in the short term. The number of analysts agreeing with this consensus is 7. The higher estimate for the short term price target is at $45 while the lower estimate is at $24. The standard deviation of the price stands at $7.28.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) witnessed a decline in the market cap on Monday as its shares dropped 1.16% or 0.19 points. After the session commenced at $16.46, the stock reached the higher end at $16.5648 while it hit a low of $15.82. With the volume soaring to 1,791,904 shares, the last trade was called at $16.15. The company has a 52-week high of $32.82. The company has a market cap of $1,592 million and there are 98,595,000 shares in outstanding. The 52-week low of the share price is $12.11.
Celldex Therapeutics, Inc. has lost 24.36% in the last five trading days and dropped 39.76% in the last 4 weeks. Celldex Therapeutics, Inc. has dropped 38.5% during the last 3-month period . Year-to-Date the stock performance stands at -11.51%.
On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Celldex Therapeutics, Inc., Ellberger Larry had purchased shares worth of $82,950 in a transaction dated on August 13, 2015. A total of 5,000 shares were purchased at a price of $16.59 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Companys drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). CDX-1127 is a human monoclonal antibody that targets CD27. CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas and leukemias. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology programs, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.